The Division of DKTK München is seeking a

Professur (W3) für Translationale Onkologie mit dem Schwerpunkt Reverse Translation (Lehrstuhl) am Standort München des Deutschen Konsortiums für Translationale Krebsforschung (DKTK)
(Ref.-No. 2020-0021)

The German Cancer Research Center (DKFZ) and the Faculty of Medicine of Ludwig-Maximilians-Universität (LMU) in Munich are jointly seeking a

Professorship (W3) of Translational Oncology with Focus on Reverse Translation (Chair) at the partner site München

of the German Cancer Consortium (DKTK)

commencing as soon as possible.

The successful candidate is expected to represent the entire field in research and teaching at the university.

The successful candidate will be working at LMU Munich, a partner site of the German Cancer Consortium (DKTK). The DKTK is formed by the DKFZ as core center and partner universities to establish a national network of translational cancer research units at seven partner sites.

The appointee will be an internationally successful scientist in reverse translation in oncology translating clinical challenges into basic cancer research. Candidates from medicine or life sciences (with medical background) with special expertise in basic and translational research are particularly encouraged to apply. The appointed professor shall intensively collaborate with the scientific and clinical community of the DKTK partner site München, the DKFZ (www.dkfz.de/en) as well as within the German Cancer Consortium (www.dktk.org).

Prerequisites for this position are a university degree, a doctoral degree or a comparable specific qualification, teaching skills at university level, excellent academic achievements and a productive and promising research program.

The future holder of this position will be appointed to LMU Munich as a university professor (W3) and will be granted leave of absence in order to be employed at the DKFZ based on an employment agreement under private law.

LMU Munich and the DKFZ Heidelberg make a point of providing newly appointed professors with various types of support, such as welcoming services and assistance for dual career couples.

The DKFZ Heidelberg and LMU Munich are equal opportunity employers. Thus they intent to increase the number of female faculty members and strongly encourage applications from female candidates. Furthermore, disabled candidates with essentially equal qualifications will be given preference.

Please submit your application comprising a curriculum vitae, documentation of academic degrees and certificates as well as a list of publications accompanied by a formal application form (see http://www.med.uni-muenchen.de) to the Dean of the Faculty Prof. Dr. R. Hickel, Bavariaring 19, 80336 Munich, Germany, and additionally to the Chairman and Scientific Director of the German Cancer Research Center, Prof. Dr. M. Baumann, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany via the DKFZ online application portal (www.dkfz.de/jobs, reference number 2020-0021) no later than 27.08.2020.

The German Cancer Consortium is a joint initiative of the German Federal Ministry of Education and Research (BMBF), the participating German states and the DKFZ. The alliance between the DKFZ as a core center, the National Center for Tumor Diseases in Heidelberg and the university partner sites in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich, and Tübingen establishes joint translational cancer research units. The DKTK promotes interdisciplinary approaches and innovative clinical studies, which will contribute to improved prevention, diagnosis faster implementation of personalized therapies for cancer patients.

Application Deadline: 27.08.2020

Contact: Prof. Dr. med. Michael Baumann, phone +49 (0)6221/42-2850

Please note that we do not accept applications submitted via email.

Job description:

Your profile:

siehe Aufgaben